Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

B&L eying $50 mil. cost cuts as part of three-year plan directed by Exec VP Carpenter.

This article was originally published in The Gray Sheet

Executive Summary

BAUSCH & LOMB EXEC VP CARPENTER TO OVERSEE $50 MIL. COST REDUCTION PROGRAM designed to "promote strong earnings recovery during 1996," the company says. B&L announced Dec. 7 that it has given William Carpenter, an executive VP and manager of its global eyewear business, responsibility for global operations of its three core businesses -- contact lenses, lens care products, and eyewear.

You may also be interested in...



Bausch & Lomb Cutting 850 Jobs To Address Global Contact Lens Market

Bausch & Lomb plans to eliminate 7% of its workforce over the next 12 months in response to increased global competition in the contact lens market, Chairman and CEO William Carpenter announced during a Dec.1 teleconference.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel